Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity

Journal of Medicinal Chemistry

Volumn 43, Issue 15, 2000, Pages 2962-2966

  Nudelman, Abraham ^a   Rephaeli, Ada ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; RETINOIC ACID DERIVATIVE; RETINOYLOXYMETHYL BUTYRATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; DRUG EFFECT; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL;

ANTINEOPLASTIC AGENTS; BUTYRATES; BUTYRIC ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0034721174     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990540a     Document Type: Article

References (36)

1. Breitman, T.; Selonick, S.; Collins, S. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 2936-2940.
2. Castaigne, S.; Chomienne, C.; Daniel, M. T.; Ballerini, P.; Berger, R.; Fenaux, P.; Degos, L. All-trans-retinoic acid as differentiation therapy for acute promyelocytic leukemia. I. Clinical Results. Blood 1990, 76, 1704-1709.
3. Prasad, K. N. Butyric Acid: A small fatty acid with diverse biological functions. Life Sci. 1980, 27, 1351-1358.
4. Kruh, J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture Mol. Cell. Biochem. 1982, 42, 65-82.
5. Rephaeli, A.; Nordenberg, J. Cytodifferentiation inducers as an anti-cancer agents. Int. J. Oncol. 1994, 1, 481-487.
6. Mangelsdrof, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, R.; Blumberg, B.; Kasmer, P.; Mark, M.; Chambon, P. The nuclear hormone receptor superfamily, the second decade. Cell 1995, 83, 835-840.
7. Minucci, S.; Pelicci P. G. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Cell Dev. Biol. 1999, 10, 215-225.
8. Chen, H.; Lin, RJ.; Xie, W.; Wilpitz, D.; Evans, R. M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 1999, 98, 675-686.
9. Davis, S. M.; Ross, J. A. Childhood cancer etiology: recent reports. Med. Pediatr. Oncol. 1999, 32, 49-52.
10. Freeman, H. J. Effect of differing concentration of sodium butyrate in 1,2-dimethylhydrazine-induced rat intestinal neoplasis. Gastroenterology 1986, 91, 596-602.
11. Miller, A. A.; Kurschel, E.; Osieka, R.; Schmidt, C. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol. 1987, 23, 1283-1287.
12. Rephaeli, A.; Nordenberg, J.; Aviram, A.; Rabizadeh, E.; Zimra, Y.; Nudelman, A.; Novogrodsky, A.; Shaklai, M. Butyrate induced differentiation in leukemic myeloid cells in vitro and in-vivo studies. Oncol. Rep. 1994, 1, 481-487.
13. Vidali, G.; Boffa, L. C.; Bradbury, E. M.; Allfrey, F. G. Butyrate suppression of histone deacetylation leads to accumulation of poly-acetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 2239-2243.
14. Candido, E. P.; Reeves, R.; Davie, J. R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14, 105-113.
15. Chen, T. A.; Allfrey, V. G. Rapid and reversible changes in nucleosome structure accompany the activation, repression, and superinduction of murine fibroblast protooncogenes c-fos and c-myc. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5252-5256.
16. Thorne, A. W.; Kmiciek, D. K.; Mitchelson, K.; Sautiere, P.; Crane-Robinson, C. Patterns of histone acetylation. Eur. J. Biochem. 1990, 193, 701-713.
17. Ogryzko, V. V.; Schiltz, R. L.; Russanova, V.; Howard, B. H.; Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87, 953-959.
18. Wolffe, A. Sinful repression. Nature 1997, 387, 16-17.
19. Fenrick, R.; Hiebert, S. W. Role of histone deacetylases in acute leukemia. J. Cell Biochem. Suppl. 1998, 30-31, 194-202.
20. Lin, R. J.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H., Jr.; Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998, 39, 811-814.
21. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol Chem. 1990, 265, 17174-17179.
22. Samid, D.; Hudgins, W. R.; Shacks, S.; Liu, L.; Prasanna, P.; Myets, C. E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. 1997, 400A, 501-505.
23. Lea, M. A.; Randolph, V. M.; Hodge, S. K. Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogues. Anticancer Res. 1999, 19, 1971-1976.
24. Warrell, R. P., Jr.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1999, 90, 1621-1625.
25. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Cioce Fanelli, M.; Ruthardt, M.; Ferrara, F. F.; Zamir, I.; Seiser, C.; Grignani, F.; Lazar, M. A.; Minucci, S.; Pelicci, P. G. Fusion proteins of the retinoic acid receptor alfa recruit histone deacetylase in promyelocytic leukemia. Nature 1998, 391, 815-816.
26. He, L. Z.; Guidez, F.; Tribioli, C.; Peruzzi, D.; Ruthardt, M.; Zelent, A.; Pandolfi, P. P. Distinct interaction of PML-RAR alfa and PLZF-RAR alfa in co-repressors determine differential responses to RA. Appl. Nat. Genet. 1998, 18, 126-135.
27. Taimi, M.; Chen, Z. X.; Breitman, T. R. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisactamide. Oncol. Res. 1998, 10, 75-84.
28. Nudelman, A.; Shaklai, M.; Aviram, A.; Rabizadeh, E.; Zimra, Y.; Ruse, M.; Rephaeli, A. Novel anticancer prodrugs of butyric acid. J. Med. Chem. 1992, 35, 6876-6894.
29. Rephaeli, A.; Shaklai, M.; Ruse, M.; Nudelman, A. Derivatives of butyric acid as potential anti-neoplastic agents. Int. J. Cancer. 1991, 49, 66-72.
30. Aviram, A.; Zimra, Y.; Shaklai, M.; Nudelman, A.; Rephaeli, A. Comparison between the effect of butyric acid and its prodrugs pivaloyxmethyl butyrate on hyperactylation of histones in HL-60 cell lines. Int. J. Cancer 1994, 56, 906-909.
31. Rabizadeh, E.; Shaklai, M.; Eisenbach, L.; Nudelman, A.; Rephaeli, A. Esterase inhibitors diminish the modulation of gene expression by butyric butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Israel J. Med. Sci. 1996, 32, 1186-1191.
32. Zimra, Y.; Wasserman, L.; Maron, L.; Shaklai, M.; Rephaeli, A.; Nudelman, A. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J. Cancer Res. Clin. Oncol. 1997, 723, 152-160.
33. Bundgaard, H. R.; Nielsen, N. M. Esters of N,N-disubstituted 2-hydroxyacetamides as novel highly biolabile prodrug type for carboxylic acid agents. J. Med. Chem. 1987, 30, 451-455.
34. Eckhart S. D.; Villaona-Calero, M. A.; Hommond, L. A phase I study of AN-9, pivaloyloxymethyl butyrate (Pivanex) a lipophilic butyric acid analogue, in patients with advanced solid tumors. Proc. AACR 1988, 80, #3449.
35. Zimra, Y.; Maron, L.; Shaklai, M.; Nudelman, A.; Rephaeli, A. Pivaloyloxymethyl butyrate (AN-9) exhibits higher anticancer activity than butyric acid (BA): It penetrates faster than the acid and induces apoptosis in HL-60 cells. Blood 1994, 84, 10.
36. Warrel, R. P.; Samid, D. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 1999, 91, 475-476.